Philippe Lambin is a Clinician, Radiation Oncologist and pioneer in translational research with a focus on hypoxia and Decision Support Systems. He has a PhD in Radiation Biology and is Professor at the University of Maastricht (Radiation Oncology) and at the University of Eindhoven (“Functional Imaging”). He is co-author of more than 354 peer reviewed scientific papers (Hirsch Index: 62), co-inventor of more than 18 patents (filed or submitted) of which 5 are in the (pre)commercialization phase and (co) promoter of more than 33 completed PhD’s.

Moreover, Prof. P. Lambin has extensive experience with clinical trials. He was one of the international experts in the Flims workshop “Methods in Clinical Cancer Research organised jointly by the FECS, AACR and ASCO and he is leading several clinical trials (see www.clinicaltrials.gov: his name is mentioned as Principal Investigator in 26 clinical trials). He was also a member of the scientific committee of KWF (the main Dutch funding body in cancer research) and of the advice committee on protontherapy of CVZ (the Dutch medical insurance).

He is currently involved in several successful European grants (e.g. CDPT, Biocare, Euroxy, Metoxia, euroCAT, Eureca, Artforce, Radiate, Requite…) and two NIH grant (“Radiomics”). His main areas of interest are directed towards translational research in Radiation Biology with aspecific focus on tumour hypoxia, functional imaging (CT-PET), lung and head and neck cancer. More recently his interests have been directed towards the development of a “treatment decision support system” based on multiparametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences (visit one of the websites he is managing: www.predictcancer.org ). He is one of the inventor of “Distributed learning” a revolutionary data mining approach for health care (watch the animation of a project he managed: youtu.be/ZDJFOxpwqEA ).

Lately, he has also been involved in Technology Transfer activities in spin-off companies of the University of Maastricht (e.g. www.oncoradiomics.com (Radiomics signatures - software combined with distributed learning solutions, due diligence being undertaken), www.pttheragnostic.com (multifactorial biomarkers, mitochondrial DNA signatures, Letter of intend for funding signed), www.dualtpharma.com (multifunctional targeted drugs, looking for funding).

In September 2012, his research group received the highest possible score (‘excellent’ – 5 - on all aspects) by an international external review committee and was described as having a “world-leading position”. The reviewers added “In large part, this is due to the inspirational leadership of Prof. P. Lambin who has done an outstanding job of building a world-class research programme within a relatively short period of time.” In February 2014, MAASTRO clinic received a licence from the Dutch Ministry of Health to start protontherapy in Maastricht. Since he started as medical Director of MAASTRO in 2000 the volume of activities, the number of FTE and the annual budget has more than tripled.

ICCR news

25 June 2016: There have been last minute changes to the programme. Please go to the Full Programme page for details.

16 June 2016: The Conference Book is now available.

Social